drugset / Trial / NCT01739621
Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To further determine the safety and efficacy of Proellex in premenopausal women with uterine fibroids who have previously completed study ZPV-200.
Timeline
- Start
- 2012-09
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telapristone Acetate | Other / unclassified | 12 mg | Intravenous |
| Subject | Telapristone Acetate | Other / unclassified | 24 mg | Intravenous |